Updated on 8 May 2015
TRXE-009 has been designed to cross the blood-brain barrier
Singapore: US-Australian drug discovery company, Novogen, in conjunction with Australian paediatric cancer researchers, have progressed on experimental cancer drug-candidate, TRXE-009, to become an important new therapy against an incurable paediatric brain cancer called DIPG (diffuse intrinsic pontine glioma).
DIPG has a very poor prognosis with a median survival of less than one year, a statistic that has not changed in over 50 years. DIPG is amongst the most challenging cancers to treat; the diffuse nature of the cancer means that surgery is not an option, radiation provides only temporary relief, and chemotherapy has yet to provide any clinical benefit.
Dr David Ziegler, lead investigator said, "These are preliminary studies but we are very excited about the striking activity we are seeing in these highly resistant tumorspheres. TRXE-009 is one of the most potent compounds we have studied to date in this setting."
Dr Eleanor Ager, Trilexium program manager, Novogen, "These findings add to our other pre-clinical studies suggesting that TRXE-009 has particular activity against brain cancers, including being highly cytotoxic against the main adult brain cancer, glioblastoma multiforme (GBM). The next step in this drug's development is to confirm its ability to cross the blood-brain barrier, a key filtering system that blocks the majority of chemotherapeutic drugs from reaching brain tissue".
TRXE-009 has been designed to cross the blood-brain barrier, but Novogen has further enlisted the combined efforts of several international research groups to identify the optimal means of delivering TRXE-009 to adults and children so that it crosses the blood-brain barrier.